Page 2 - Mecklenburg_Medicine_October-2020

Reimagining
cancer care
for Charlotte

In addition to the expert hematology care you have come to expect, Novant Health Cancer Institute
now offers easier access to leading-edge therapies for patients with complex and advanced
hematologic cancers, including:

• Hematopoietic cell transplantation

• Chimeric Antigen Receptor T-cell (CAR-T) therapy
• More than 20 phase 1, 2, and 3 hematology clinical trials for experimental treatments and protocols Omotayo Fasan, MD

Malignant hematology services have been expanded, thanks to the teams led by Omotayo Fasan,
MD, director of hematology and the transplantation and cellular therapy program, Alan Skarbnik, MD,
director of the lymphoproliferative disorders and experimental therapeutics programs, and Kimberly
Green, DO, hematologist.

Our newest treatment option is CAR-T cell therapy for patients with relapsed diffuse large B-cell and Alan Skarbnik, MD
mantle cell lymphomas. CAR-T therapy is offered at 90 medical centers nationwide; most of which
are large academic institutions.

After CAR-T infusion, patients must be monitored frequently — a key reason for seeking treatment
close to home.

“Our patients have a hard disease to deal with and they’re scared,” Dr. Skarbnik said. Kimberly Green, DO
“We’re building relationships for life with these patients. We’re here for them, and we’ll be
here with them for many years.”

All new patients will be seen within 48 hours. Dedicated care
coordinators will expedite the referral process. Call us at 704-316-3297.

© Novant Health, Inc. 2020
9/20 • GCM-538082